Oragenics Touts New Drug to Fight Clostridium Difficile (Proactive Investors)

New research by Sid Martin Biotech alum Oragenics Inc., now a Tampa-based clinical-stage biotech group, has uncovered a novel type of antibiotic known as a lantibiotic for the treatment of clostridium difficile, an infection causing colitis, called OG716.

When golden Syrian hamsters infected with clostridium difficile were treated with the drug OG716, a variant of the lantibiotic Mutacin 1140, 100% survived and were cured of the disease. Also, the hamsters did not suffer a relapse of the disease after three weeks since the time they were infected.

Given its success in treating clostridium difficile, Oragenics is looking to submit an investigational new drug application for OG716 next year.

Learn more about Oragenics Touts New Drug to Fight Clostridium Difficile.